Skip to content
DataLookout
Menu

ENDEAVOUR-UCNCT06398626

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

StatusActive, Not Recruiting
PhaseNot specified
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 16 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Study sites: 29 to 26
    • Study completion date: Jul 7, 2028 to Jul 1, 2028
  2. Notable Eligibility criteria expanded, about 14 words
    • Study sites: 28 to 29
    • Secondary endpoints: details revised at 4 of 13 entries
  3. Minor Trial sites expanded: 22 → 28 locationsv14
  4. Minor Study sites revised (22)v13
  5. Minor Primary completion date: May 4, 2027 to Oct 1, 2027v12
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Eligibility criteria expanded, about 4 words
    • Study sites: 14 to 22
    • Study completion date: Sep 15, 2027 to Jul 7, 2028
    • Secondary endpoints revised (13)
    v11
  2. Minor Study sites: 13 to 14v10
  3. Minor Site details revised at 1 of 13 sitesv9
  4. Minor Study sites: 11 to 13v8
  5. Minor Study sites: 10 to 11
    • Start date changed from estimate of Sep 30, 2024 to Sep 17, 2024
    v7
  6. Notable Start date: Aug 27, 2024 to Sep 30, 2024
    • Study completion date: Aug 15, 2027 to Sep 15, 2027
    • Secondary endpoints: details revised at 2 of 13 entries
    v6
  7. Minor Study sites: 8 to 10v5
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Aug 15, 2024 to Aug 27, 2024
    • Site details revised at 8 of 8 sites
    v4
  9. Minor Study sites: 0 to 8
    • Study completion date: Feb 28, 2028 to Aug 15, 2027
    • Start date: Jul 22, 2024 to Aug 15, 2024
    v3
  10. Notable Start date: May 15, 2024 to Jul 22, 2024v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients with symptomatic remission
Timeframe: Week 12

Secondary (12)

Proportion of patients with symptomatic remission
Proportion of patients with symptomatic response
Proportion of patients with clinical remission
Proportion of patients with steroid-free symptomatic remission (among all patients and among patients in symptomatic remission)
Proportion of patients with steroid-free clinical remission (among all patients and among patients in clinical remission)
Show 7 moreShow less
Change from baseline in fatigue
Change from baseline of bowel urgency
Proportion of patients with a clinically meaningful improvement in bowel urgency
Proportion of patients in bowel urgency remission
Proportion of patients with complete bowel urgency remission
Change from baseline in abdominal pain
Proportion of patients with abdominal pain remission

Arms and interventions

Adult patients with ulcerative colitis taking etrasimod

Drugs: Etrasimod

Sites

26 sites in 1 country